Centene (CNC), Why Everyone Is Watching Its Latest Update

Why Centene’s latest debt move matters for investors

Centene (CNC) is drawing fresh attention after delivering a notice of redemption for all remaining $568.7m of its 4.25% notes due December 2027, with repayment set for October 23, 2026.

This debt retirement lands just weeks before the company is expected to report third quarter 2026 earnings. Investors are already focused on Medicaid membership pressures and on how updated guidance lines up with recent share performance.

Recent news around Centene’s note redemption and the Ambetter collaboration with Marathon Health has landed against a strong run in the stock, with a year to date share price return of 56.44% and a 1 year total shareholder return of 82.77%. This comes even as the 3 year total shareholder return is slightly negative and momentum over the past 90 days has cooled with a 2.95% decline in the share price return.

Spot opportunities beyond Centene’s latest moves and compare how other insurers are positioned on debt, membership trends, and earnings momentum with our hand picked list of solid balance sheet and fundamentals (25 results).

Centene has already delivered a powerful rebound and cleaned up a slice of its debt, yet Medicaid pressure and profit expectations still hang over the story. Is most of the upside already priced in, or is the market underestimating what comes next?

Most Popular Narrative: 9% Undervalued

Centene’s most followed narrative pegs fair value at $71.78, above the recent close of $65.36. This frames the recent rally against a still implied discount based on long term earnings power.

Centene's effort to restore Medicaid margins, supported by a 2026 composite rate yield outlook of roughly 5% and a targeted full year Medicaid HBR of about 93.5%, continues to point to earnings power that some investors may not yet fully reflect in valuation, with potential impact on segment net margins.

See why 57 investors see Centene as 9% undervalued.

Result: Fair Value of $71.78 (UNDERVALUED)

Still, the Centene narrative can crack if Medicaid membership declines of 8% to 9% and any weaker Marketplace support outpace planned pricing and cost controls.

Find out about the key risks to this Centene narrative.

Next Steps

The mix of optimism and caution around Centene only matters if you weigh the evidence yourself and move before the next narrative shift, so pressure test your own thesis against the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Centene?

If you stop with Centene, you risk missing other opportunities surfaced by the Simply Wall Street Screener that could better match your risk, income, or value goals.

• Target resilient balance sheets and steadier fundamentals by scanning our list of solid balance sheet and fundamentals (25 results), which is tailored to highlight financially robust businesses.
• Hunt for value where quality and pricing still look attractive with a focused sweep of the 28 high quality undervalued stocks.
• Build a cash-flow-focused portfolio and stress test your income plan using the 8 dividend fortresses, which is built around higher-yielding opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com